Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Uterine Cervical Neoplasms 18Prostatic Neoplasms 18Sarcoma 5Neoplasms 4Uterine Neoplasms 2Rhabdomyosarcoma 2Rectal Neoplasms 2Liver Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Dysplasia 1To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer 1Retinoblastoma 1Prostate Cancer With Intermediate Risk 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Metastatic Malignant Female Reproductive System Neoplasm 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation 1Endometrial Adenocarcinoma 1Desmoplastic Small Round Cell Tumor 1Cholangiocarcinoma 1

Interventions

Oxaliplatin 26Gemcitabine 22Fluorouracil 17Capecitabine 16Leucovorin 15pembrolizumab 14Docetaxel 14Cisplatin 13Bevacizumab 12Radiotherapy 8Paclitaxel 8Irinotecan 8Trastuzumab 7Pemetrexed 6Carboplatin 6130-nm albumin-bound paclitaxel 6durvalumab 5cemiplimab 5Erlotinib Hydrochloride 5Sunitinib 4Ramucirumab 4Metformin 4Gefitinib 4trastuzumab deruxtecan 3tislelizumab 3cabozantinib 3atezolizumab 3Taxes 3Sorafenib 3Panitumumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenocarcinoma × Brachytherapy × Clear all
NCT01301612 2014-07-14

Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

Eurofarma Laboratorios S.A.

Phase 2 Withdrawn
Tumor-Agnostic

Adenocarcinoma, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡